Investors

Corporate Overview

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing aritinercept, a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases.

Download Corporate Presentation
Aurinia Corporate Presentation November 2025
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of applicable U.S. securities law and forward-looking information within the meaning of applicable Canadian securities law.
Changing the Trajectory of Autoimmune Diseases
Recent Financial Results
Results for the Three Months Ended September 30
Results for the Nine Months Ended September 30
Cash Flows and Financial Position
2025 Financial Guidance
LUPKYNIS® – A calcineurin inhibitor (CNI) indicated in combination with a background immunosuppressive regimen for the treatment of adult patients with active lupus nephritis. The first oral therapy approved for the treatment of lupus nephritis
Lupus Nephritis (LN) Is Among the Most Severe and Dangerous Complications of Systematic Lupus Erythematosus (SLE)
Proteinuria Reduction Is Associated with Long-Term Renal Preservation
Recent American College of Rheumatology (ACR)Lupus Nephritis Treatment Guideline Update
LUPKYNIS Is a Novel, Structurally Modified CNI that Targets LN with a Dual Mechanism of Action
Robust Clinical Study History
Significantly More Patients on LUPKYNIS Achieved a Complete Renal Response in AURORA 1 as Early as Week 24
LUPKYNIS Rapidly Reduced Proteinuria in Fewer Days in AURORA 1
New Analysis Shows LUPKYNIS Associated with 53% Reduction in Risk of Renal-Related Event or Death
Adverse Reactions Occurring in ≥3% of Patients Treated with LUPKYNIS 23.7 mg Twice a Day and ≥2% Higher than Placebo in AURORA 1 and AURA-LV
Aritinercept – A dual BAFF/APRIL inhibitor for the potential treatment of autoimmune diseases
Aritinercept Is a Dual BAFF/APRIL Inhibitor
Role of BAFF and APRIL
Aritinercept Is a High Affinity Dual BAFF/APRIL Inhibitor
Aritinercept Potently Inhibits BAFF-and APRIL-Mediated B Cell Proliferation
Aritinercept Single Ascending Dose (SAD) Study: Design
Aritinercept SAD Study:Safety Summary
Aritinercept SAD Study: Single Doses of Aritinercept Led to Robust and Long-Lasting Reductions in Immunoglobulins in Humans
Effect of a Single Dose of BAFF/APRIL Inhibitors on IgA
Effect of a Single Dose of BAFF/APRIL Inhibitors on IgM
Effect of a Single Dose of BAFF/APRIL Inhibitors on IgG
Summary and Next Steps
Aurinia Pharmaceuticals Inc., 2025. All rights reserved.

Email Alerts

By providing your email address above, you are providing consent to Aurinia Pharmaceuticals Inc. to send you the requested Investor Email Alert updates. For information on how we protect your information, please refer to our Privacy Policy.
Thank you. Your request has been received.
Oops! There was an error with your submission.

Stock Information

NASDAQ Global Market: AUPH

$14.185

+1.015

/

+7.71%

3.85M

Volume

Last update:
11/04/2025 1:45PM ET
Pricing delayed by 15 minutes

Upcoming Events

There are no upcoming events scheduled at this time.

Past Events

Select Year
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Nov 4
-
Nov 4, 2025
Nov 4, 2025 8:30 AM
EDT
2025

Third Quarter 2025 Financial Results Conference Call

Press Release10-QWebcastPresentationFinancials and MDA - IFRSFinancials - US GAAPFinancials and MDA
Jul 31
-
Jul 31, 2025
Jul 31, 2025 8:30 AM
EDT
2025

Second Quarter 2025 Financial Results Conference Call

Press Release10-QWebcastPresentationFinancials and MDA - IFRSFinancials - US GAAPFinancials and MDA
Jun 30
-
Jun 30, 2025
Jun 30, 2025 8:30 AM
EDT
2025

Conference Call to Discuss Positive Results from Phase 1 Study of Aritinercept (AUR200)

Press ReleaseWebcastPresentationFinancials and MDA - IFRSFinancials - US GAAPFinancials and MDA
May 21
-
May 24, 2025
May 21, 2025 11:30 AM
2025

LUPUS 2025, the 16th International Congress on SLE

Press ReleaseWebcastPresentationFinancials and MDA - IFRSFinancials - US GAAPFinancials and MDA
May 15
-
May 15, 2025
May 15, 2025 12:00 PM
EDT
2025

2025 Annual General Meeting

Press ReleaseWebcastPresentationFinancials and MDA - IFRSFinancials - US GAAPFinancials and MDA
No Results Found
Please try different keywords or filters.

SEC Filings

Select Year
Form Types
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Date
Filing Type
Description
Download
Date
January 22, 2019
2019
Filing Type
6-K
Description
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
Current Reports
Download
Date
January 18, 2019
2019
Filing Type
SC 13D/A
Description
Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities
Section 16 Filings
Download
Date
November 30, 2018
2018
Filing Type
SUPPL
Description
Voluntary supplemental material filed pursuant to Section 11(a) of the Securities Act of 1933 by foreign issuers
Other
Download
Date
November 30, 2018
2018
Filing Type
6-K
Description
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
Current Reports
Download
Date
November 8, 2018
2018
Filing Type
6-K
Description
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
Current Reports
Download
No Results Found
Please try different keywords or filters.

Governance

Committee Charter Documents
Audit Committee Charter
Download
Compensation Committee Charter
Download
Corporate Governance Committee Charter
Download
Disclosure Committee Charter
Download
Governance Documents
Anti-Fraud Policy
Articles
Certificate and Articles of Amendment
Certificate of Amalgamation
Code of Ethics and Conduct
Conformed By-Law No. 2
Corporate Disclosure Policy
Forced Labour Report
Indemnity Policy
Information for Vermont Prescribers
Insider Trading Policy
Majority Voting Policy
Mandate of the Board of Directors
Position Description - CFO
Position Description - President - CEO
Terms of Reference - Chairman
Whistleblower Policy

IR Contact

General inquiries can be sent to ir@auriniapharma.com